LifeScience PLUS

Executive Summary

LifeScience PLUS is a private, pre-clinical stage company headquartered in San Diego, focused on advanced wound care solutions. Its flagship product, BloodSTOP® iX Advanced Hemostat with WoundHEAL®, is a patented, best-in-class hemostat designed to control bleeding, seal wounds, prevent contamination, and promote rapid tissue regeneration for both acute and chronic wounds. The company aims to address the significant unmet need in the wound care market, which is driven by an aging population, rising chronic disease prevalence, and increasing surgical volumes. Despite being founded in 2017, LifeScience PLUS remains in the pre-clinical phase, indicating that its technology has not yet undergone human clinical trials. The company's success hinges on successfully navigating regulatory pathways, demonstrating safety and efficacy in clinical studies, and securing partnerships or funding to advance its product pipeline. Given its pre-clinical status, LifeScience PLUS is at an early stage of development with substantial risk but also significant upside potential if its technology proves effective. The wound care market is large and competitive, but the company's claims of a game-changing platform could differentiate it if validated. Key near-term milestones include initiating first-in-human studies, establishing manufacturing partnerships, and obtaining additional capital to fund operations. The company's ability to achieve these catalysts will determine its trajectory toward commercialization and eventual revenue generation.

Upcoming Catalysts (preview)

• Q4 2026IND Filing or Regulatory Submission to Begin First-in-Human Trial60% success
• TBDStrategic Partnership or Licensing Deal for Wound Care Technology50% success
• Q3 2026Publication of Preclinical Efficacy Data in Peer-Reviewed Journal70% success